Health Benefits of Whole-body Vibration
ConditionWhole-body Vibration
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorAugusta University
About this trial
The overall goals of this pilot investigation are to determine 1) the feasibility of conducting home based WBV studies, and 2) to determine if sub-acute home based WBV can improve a) exercise capacity, b) conduit- and micro- vascular function, and c) skeletal muscle function.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Men and women (> 18 yrs old)
All races
Disqualifiers
<18 years old
Clinical diagnosis of hepatic, cardiovascular, or renal disease
Diabetic complications (i.e. macrovascular, microvascular, or autonomic)
Pregnancy
Trial design
Design model
Single group
Treatments tested in this trial
Sub Acute Whole Body Vibration Training
Other interventionParticipants will be given a personal vibration plate to take home with them for training which will last for 12 weeks. For the first four weeks, participants will be asked to complete 10 minutes of WBV per day (1 minute on and up to 1 minute of rest), at least 3-4 days per week. At least 24 hours will be recommended in between sessions during weeks 1-4. Beginning at week 5, participants will be asked to increase WBV time to up to 14 minutes and/or reduce the duration of rest. Beginning at week 9, participants will be asked to increase WBV time to up to 20 minutes and/or reduce the duration of rest.
Treatment groups
40 Participants
are divided into 1 treatment groupGroup A: Sub Acute (12 week) Whole Body TrainingExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
Change in VO2 Peak
change from baseline relative (mL/kg/min) peak oxygen consumption (VO2) during maximal exercise test at 12 weeks
Time frame
pre-treatment baseline and following 12 weeks sub-acute whole-body vibration2
Change in Flow-Mediated Dilation (FMD)
change from baseline brachial artery flow mediated dilation at 12 weeks.
Time frame
pre-treatment baseline and following 12 weeks sub-acute whole-body vibration3
Change in Skeletal Muscle Mitochondrial Function
change from baseline skeletal muscle mitochondrial function at 12 weeks. Measured using Near Infrared Spectroscopy (NIRS). Values are an index of phosphocreatine recovery expressed as a rate constant (min-1)
Time frame
pre-treatment baseline and following 12 weeks sub-acute whole-body vibration4
Change in Pulse Wave Velocity (PWV)
Change from baseline PWV at 12 weeks. Measured by Shygmocor Xcel in m/s.
Time frame
pre-treatment baseline and following 12 weeks sub-acute whole-body vibrationSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov